[Corticosteroid resistance thrombocytopenia in connective tissue disorders and vasculitis].
In rheumatic diseases there can appear deteriorations of the thrombocytes number in the sense of increase or decrease of this number.Thrombocytosis has 3 major causes: (1) reactive or secondary thrombocytosis; (2) family thrombocytosis and (3) clonal thrombocytosis. Thrombocytopenia, that is, decrease of the thrombocytes number below 150000/mmc is unusually in rheumatic diseases. Their mechanism of production can be central and peripheral. In the connective tissue disorders and vasculitis thrombocytopenia can has different causes: (1) decrease thrombocytes production; (2) splenic platelets sequestration; (3) peripheral platelets consumption; (4) peripheral immune mediated destruction of platelets. Thrombocytopenia is present in the following rheumatic diseases: systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, Felty syndrome, vasculitis. Steroids are the conventional first line therapy for immune thrombocytopenia. Corticosteroid resistance can develop as a result of deteriorations that appear to the any level of pathway action of corticosteroids.
Rezuş
Elena
E
Universitatea de Medicină şi Farmacie Gr. T. Popa, Iaşi, Facultatea de Medicină, Clinica I Reumatologie si Recuperare Medicală.
Rezuş
C
C
Răşcanu
Anca
A
Bârzoi
Raluca
R
Rodica
Chiriac
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000465:Algorithms; D016736:Antiphospholipid Syndrome / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003240:Connective Tissue Diseases / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance; D005258:Felty Syndrome / Q000188:drug therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014657:Vasculitis / Q000150:complications / Q000188:drug therapy*